1. Edition - July 2007
93.90 Euro
2007. 296 Pages, Hardcover
- Handbook/Reference Book -
ISBN-10: 0-471-75215-0
ISBN-13: 978-0-471-75215-8 - John Wiley & Sons






Sample Chapter

Short description
The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is provided, as well as background to the biology, pharmacology, pharmacokinetics, and drug metabolism, followed by a detailed account of the drug synthesis. Edited by prominent scientists working in drug discovery for Pfizer, this book meets the needs of a growing community of researchers in pharmaceutical R&D, providing a useful guide for practicing pharmaceutical scientists as well as a text for medicinal chemistry students. It provides an excellent follow-up to the very successful first book by these editors, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed.

From the contents
Foreword.

Preface.

Contributors.

1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY (John A. Lowe, III).

References.

2 PROCESS RESEARCH: HOW MUCH? HOW SOON? (Neal G. Anderson).

References.

I CANCER AND INFECTIOUS DISEASES.

3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) (Jie Jack Li).

References.

4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) (Chris Limberakis).

References.

5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) (Andrew S. Bell).

References.

6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS (Arthur Harms).

References.

7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) (Douglas S. Johnson and Jie Jack Li).

References.

II CARDIOVASCULAR AND METABOLIC DISEASES.

8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES (Jin Li).

References.

9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION (Larry Yet).

References.

10 LEADING ACE INHIBITORS FOR HYPERTENSION (Victor J. Cee and Edward J. Olhava).

References.

11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION (Daniel P. Christen).

References.

12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS (Jeffrey A. Pfefferkorn).

References.

13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) (Stuart B. Rosenblum).

References.

III CENTRAL NERVOUS SYSTEM DISEASES.

14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION (Marta Piñeiro-Núñez)

References.

15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON (Peter R. Guzzo).

References.

16 a2d LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) (Po-Wai Yuen).

References.

17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) (David L. Gray).

References.

Index.